Drug Profile


Alternative Names: ND-0801; Opipramol/nicotine

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroDerm
  • Class Alkaloids; Behavioural disorder therapies; Pyridines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Histamine H1 receptor antagonists; Nicotinic receptor agonists; Opioid receptor agonists; Serotonin 2 receptor agonists; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Attention-deficit hyperactivity disorder

Most Recent Events

  • 18 Oct 2017 NeuroDerm has been acquired by Mitsubishi Tanabe Pharma Corporation
  • 01 Jan 2016 Phase I/II development is ongoing in Israel
  • 05 Nov 2012 NeuroDerm completes enrolment in its phase I/IIa trial for Attention-deficit hyperactivity disorder in Israel (NCT01174355)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top